Literature DB >> 22101319

Hyperglycosylated hCG, hCGβ and Hyperglycosylated hCGβ: interchangeable cancer promoters.

Laurence A Cole1, Stephen Butler.   

Abstract

INTRODUCTION: Several groups are researching cancers, and showing that hCGβ is a promoter of cancer growth and malignancy. Recent research shows that some hCGβ is present as Hyperglycosylated hCGβ. Other groups studied Hyperglycosylated hCG as a promoter of choriocarcinoma and germ cell malignancies. The question therefore arises, are Hyperglycosylated hCG, hCGβ and Hyperglycosylated hCGβ interrelated or interchangable promoters of cancer?
METHODS: The actions of Hyperglycosylated hCGβ, hCGβ and Hyperglycosylated hCG are investigated in 7 cell lines, Jar and JEG-3 choriocarcinoma cell lines, NTERA germ cell cancer line, SCaBER and T24 bladder epithelial carcinoma lines, KLE and Hec-1-a endometrial adenocarcinoma and epithelial carcinoma cell lines. Actions of promoters on cell growth are investigated.
RESULTS: The actions of Hyperglycosylated hCG, hCGβ and Hyperglycosylated hCGβ appear to be interchangeable in all cell lines investigated. DISCUSSION: All hCG-related cancer promoters seem interrelated, working through a similar mechanism, antagonism of apoptosis through know receptors such as TGFβ receptors in all cancers studied.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22101319     DOI: 10.1016/j.mce.2011.10.029

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  21 in total

1.  Human chorionic gonadotropin is expressed virtually in all intracranial germ cell tumors.

Authors:  Hirokazu Takami; Shintaro Fukushima; Kohei Fukuoka; Tomonari Suzuki; Takaaki Yanagisawa; Yuko Matsushita; Taishi Nakamura; Hideyuki Arita; Akitake Mukasa; Nobuhito Saito; Masayuki Kanamori; Toshihiro Kumabe; Teiji Tominaga; Keiichi Kobayashi; Motoo Nagane; Toshihiko Iuchi; Kaoru Tamura; Taketoshi Maehara; Kazuhiko Sugiyama; Mitsutoshi Nakada; Yonehiro Kanemura; Masahiro Nonaka; Kiyotaka Yokogami; Hideo Takeshima; Yoshitaka Narita; Soichiro Shibui; Yoichi Nakazato; Ryo Nishikawa; Koichi Ichimura; Masao Matsutani
Journal:  J Neurooncol       Date:  2015-05-21       Impact factor: 4.130

2.  HCG variants, the growth factors which drive human malignancies.

Authors:  Laurence A Cole
Journal:  Am J Cancer Res       Date:  2011-11-20       Impact factor: 6.166

3.  Significance of human chorionic gonadotropin as a predictor of resistance to standard chemo-radiotherapy for pure germinoma.

Authors:  Akihiro Inoue; Takanori Ohnishi; Shohei Kohno; Shiro Ohue; Shinji Iwata; Shirabe Matsumoto; Masahiro Nishikawa; Saya Ozaki; Yawara Nakamura; Yosuke Mizuno; Riko Kitazawa; Takeharu Kunieda
Journal:  Neurosurg Rev       Date:  2017-08-18       Impact factor: 3.042

4.  CGB activates ERK and AKT kinases in cancer cells via LHCGR-independent mechanism.

Authors:  Aleksandra Głodek; Anna Jankowska
Journal:  Tumour Biol       Date:  2014-02-20

5.  Absence of TGF-β Receptor Activation by Highly Purified hCG Preparations.

Authors:  Hannu Koistinen; Laura Hautala; Katri Koli; Ulf-Håkan Stenman
Journal:  Mol Endocrinol       Date:  2015-10-23

6.  Recognition of N-glycoforms in human chorionic gonadotropin by monoclonal antibodies and their interaction motifs.

Authors:  Daoyuan Li; Ping Zhang; Fei Li; Lequan Chi; Deyu Zhu; Qunye Zhang; Lianli Chi
Journal:  J Biol Chem       Date:  2015-08-03       Impact factor: 5.157

7.  Direct and rapid mass spectral fingerprinting of maternal urine for the detection of Down syndrome pregnancy.

Authors:  Ray K Iles; Maryam E Shahpari; Howard Cuckle; Stephen A Butler
Journal:  Clin Proteomics       Date:  2015-03-24       Impact factor: 3.988

8.  Endometrial carcinoma with ectopic human chorionic gonadotropin expression.

Authors:  Regina Lee; Roland Pattillo; Mark Bouzyk; Gabriela Oprea-Ilies; Roland Matthews
Journal:  Gynecol Oncol Rep       Date:  2015-03-11

9.  Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract.

Authors:  J Douglas; A Sharp; C Chau; J Head; T Drake; M Wheater; T Geldart; G Mead; S J Crabb
Journal:  Br J Cancer       Date:  2014-02-20       Impact factor: 7.640

10.  Sex differences in the MB49 syngeneic, murine model of bladder cancer.

Authors:  Shai White-Gilbertson; Megan Davis; Christina Voelkel-Johnson; Laura M Kasman
Journal:  Bladder (San Franc)       Date:  2016-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.